Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer

doi:10.3760/cma.j.cn371439-20211215-00069

Abstract

Abstract:

Triple negative breast cancer is a subtype of breast cancer with poor prognosis and lack of effective treatment. Cyclin dependent kinase（CDK）4/6 inhibitors promote antitumor immunity by influencing the triple negative breast cancer immune microenvironment, such as increasing the tumor cell surface pragrammed death-ligand 1 protein expression, enhancing T cell activation and antigen presentation, changing the proportion of T cell subgroup and inducing lymphocyte infiltration. The change of immune microenvironment is related to tumor progression, but its mechanism is extremely complex. Exploring the mechanism of CDK4/6 inhibitor affecting immune microenvironment and its biomarkers can provide a new direction for the diagnosis and treatment of triple negative breast cancer.

Key words: Triple negative breast neoplasms, Tumor microenvironment, Cell cycle, Immunocheckpoint inhibitors

Wu Jiayi, Chen Keyu, Shao Xiying, Wang Xiaojia. Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer[J]. Journal of International Oncology, 2022, 49(6): 362-365.

References 26

[1]	Shen M, Pan H, Chen Y, et al. A review of current progress in triple-negative breast cancer therapy[J]. Open Med (Wars), 2020, 15(1): 1143-1149. DOI: 10.1515/med-2020-0138. doi: 10.1515/med-2020-0138
[2]	Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. doi: 10.1016/S0140-6736(20)32531-9
[3]	de Melo Gagliato D, C Buzaid A, Perez-Garcia JM, et al. CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: current practice and knowledge[J]. Cancers (Basel), 2020, 12(9): 2480. DOI: 10.3390/cancers12092480. doi: 10.3390/cancers12092480
[4]	Roberts PJ, Kumarasamy V, Witkiewicz AK, et al. Chemotherapy and CDK4/6 inhibitors: unexpected bedfellows[J]. Mol Cancer Ther, 2020, 19(8): 1575-1588. DOI: 10.1158/1535-7163.MCT-18-1161. doi: 10.1158/1535-7163.MCT-18-1161
[5]	Bonelli M, La Monica S, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: from cell cycle arrest to immu-nomodulation[J]. Biochem Pharmacol, 2019, 170: 113676. DOI: 10.1016/j.bcp.2019.113676. doi: 10.1016/j.bcp.2019.113676
[6]	Uzhachenko RV, Bharti V, Ouyang Z, et al. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors[J]. Cell Rep, 2021, 35(1): 108944. DOI: 10.1016/j.celrep.2021.108944. doi: 10.1016/j.celrep.2021.108944
[7]	Fleisher B, Lezeau J, Werkman C, et al. In vitro to clinical translation of combinatorial effects of doxorubicin and abemaciclib in Rb-positive triple negative breast cancer: a systems-based pharmacokinetic/pharmacodynamic modeling approach[J]. Breast Cancer (Dove Med Press), 2021, 13: 87-105. DOI: 10.2147/BCTT.S292161. doi: 10.2147/BCTT.S292161
[8]	Franzoi MA, de Azambuja E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to explain different results?[J]. ESMO Open, 2020, 5(6): e001112. DOI: 10.1136/esmoopen-2020-001112. doi: 10.1136/esmoopen-2020-001112
[9]	Ameratunga M, Kipps E, Okines AFC, et al. To cycle or Fight-CDK4/6 inhibitors at the crossroads of anticancer immunity[J]. Clin Cancer Res, 2019, 25(1): 21-28. DOI: 10.1158/1078-0432.CCR-18-1999. doi: 10.1158/1078-0432.CCR-18-1999 pmid: 30224338
[10]	Di Sante G, Pagé J, Jiao X, et al. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology[J]. Expert Rev Anticancer Ther, 2019, 19(7): 569-587. DOI: 10.1080/14737140.2019.1615889. doi: 10.1080/14737140.2019.1615889
[11]	Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase desta-bilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686): 91-95. DOI: 10.1038/nature25015. doi: 10.1038/nature25015
[12]	Teh JLF, Aplin AE. Arrested developments: CDK4/6 inhibitor resis-tance and alterations in the tumor immune microenvironment[J]. Clin Cancer Res, 2019, 25(3): 921-927. DOI: 10.1158/1078-0432.CCR-18-1967. doi: 10.1158/1078-0432.CCR-18-1967
[13]	Zhang QF, Li J, Jiang K, et al. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner[J]. Theranostics, 2020, 10(23): 10619-10633. DOI: 10.7150/thno.44871. doi: 10.7150/thno.44871
[14]	Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhi-bitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade[J]. Cell Rep, 2018, 22(11): 2978-2994. DOI: 10.1016/j.celrep.2018.02.053. doi: S2211-1247(18)30234-1 pmid: 29539425
[15]	Charles A, Bourne CM, Korontsvit T, et al. Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy[J]. Oncoimmunology, 2021, 10(1): 1916243. DOI: 10.1080/2162402X.2021.1916243. doi: 10.1080/2162402X.2021.1916243
[16]	Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity[J]. Nature, 2017, 548(7668): 471-475. DOI: 10.1038/nature23465. doi: 10.1038/nature23465
[17]	Petroni G, Formenti SC, Chen-Kiang S, et al. Immunomodulation by anticancer cell cycle inhibitors[J]. Nat Rev Immunol, 2020, 20(11): 669-679. DOI: 10.1038/s41577-020-0300-y. doi: 10.1038/s41577-020-0300-y
[18]	Huang H, Zhou J, Chen H, et al. The immunomodulatory effects of endocrine therapy in breast cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 19. DOI: 10.1186/s13046-020-01788-4. doi: 10.1186/s13046-020-01788-4
[19]	Heckler M, Ali LR, Clancy-Thompson E, et al. Inhibition of CDK4/6 promotes CD8 T-cell memory formation[J]. Cancer Discov, 2021, 11(10): 2564-2581. DOI: 10.1158/2159-8290.CD-20-1540. doi: 10.1158/2159-8290.CD-20-1540 pmid: 33941591
[20]	Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy[J]. J Immunother Cancer, 2020, 8(2): e000847. DOI: 10.1136/jitc-2020-000847. doi: 10.1136/jitc-2020-000847
[21]	Sobhani N, D'Angelo A, Pittacolo M, et al. Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer[J]. Cells, 2019, 8(4): 321. DOI: 10.3390/cells8040321. doi: 10.3390/cells8040321
[22]	Shen H, Yang ES, Conry M, et al. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies[J]. Genes Dis, 2019, 6(3): 232-246. DOI: 10.1016/j.gendis.2019.06.006. doi: 10.1016/j.gendis.2019.06.006
[23]	Wang H, Najibi AJ, Sobral MC, et al. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors[J]. Nat Commun, 2020, 11(1): 5696. DOI: 10.1038/s41467-020-19540-z. doi: 10.1038/s41467-020-19540-z pmid: 33173046
[24]	Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge[J]. Cells, 2019, 8(9): 957. DOI: 10.3390/cells8090957. doi: 10.3390/cells8090957
[25]	Agostinetto E, Caparica R, Caparica E. CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?[J]. ESMO Open, 2020, 5(6): e001132. DOI: 10.1136/esmoopen-2020-001132. doi: 10.1136/esmoopen-2020-001132
[26]	Volpari T, de Santis F, Bracken AP, et al. Anticancer innovative therapy: highlights from the ninth annual meeting[J]. Cytokine Growth Factor Rev, 2020, 51: 1-9. DOI: 10.1016/j.cytogfr.2019. 12.002. doi: 10.1016/j.cytogfr.2019. 12.002